Bellwether Advisors’s Intellia Therapeutics NTLA Stock Holding History

Bellwether Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30	Closed	-$2K	–	523
2022 Q1	$2K	Hold	30	–	–	﹤0.01%	466
2021 Q4	$3K	Sell	30 -11,721	-100%	-$1.47M	﹤0.01%	463
2021 Q3	$1.58M	Buy	+11,751	New	+$1.78M	0.52%	44
2021 Q2	–	Sell	-72	Closed	-$5K	–	455
2021 Q1	$5K	Sell	72 -8	-10%	-$537	﹤0.01%	300
2020 Q4	$4K	Buy	+80	New	+$2.9K	﹤0.01%	280

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bellwether Advisors's NTLA Position: Q2 2022 in Review

Bellwether Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 30 shares — an estimated $2K sold.

Bellwether Advisors first reported a position in NTLA in Q4 2020 and held it in 5 quarters. The position peaked at $1.58M in Q3 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Bellwether Advisors reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Bellwether Advisors sold 30 Intellia Therapeutics shares in Q2 2022, an estimated $2K.
Bellwether Advisors first reported a position in Intellia Therapeutics in Q4 2020 and held it in 5 quarters.
Bellwether Advisors's Intellia Therapeutics position peaked at $1.58M in Q3 2021.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Bellwether Advisors's 13F filing for Q2 2022, filed 5 Aug 2022.